Field Medical Presents Positive Field PULSE Data
Analysis based on 8 articles · First reported Feb 05, 2026 · Last updated Feb 06, 2026
The positive clinical trial data from Field Medical's Field PULSE study is expected to positively impact the medical technology market, particularly in cardiac arrhythmia treatment. It suggests a promising new solution that could improve patient outcomes and procedural efficiency, potentially increasing investor confidence in innovative medical device companies.
Field Medical, Inc., a clinical-stage medical technology company, announced the presentation of late-breaking clinical trial data from its first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026. The study evaluated the FieldForce Ablation System, a novel high-voltage, sub-second pulsed field waveform delivery system for complex cardiac arrhythmias. The results demonstrated instantaneous energy delivery, procedural efficiency with a median bilateral pulmonary vein isolation time of 12.5 minutes, and strong PVI durability (94.2% by vein, 84.6% by patient). Importantly, the study reported no device-related serious adverse events, acute kidney injury, phrenic nerve palsy, clinically relevant hemolysis, or silent cerebral lesions. These findings extend Field Medical's clinical evidence beyond ventricular arrhythmias to atrial fibrillation, supporting a versatile ablation platform for all heart chambers. The company previously earned Breakthrough Device Designation and entry into the FDA TAP Pilot Program for its ventricular tachycardia indication.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard